Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $44.11 USD
Change Today -0.0399 / -0.09%
Volume 1.1M
As of 11:36 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GSK) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/3/14 - $54.78
52 Week Low
01/6/15 - $41.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

glaxosmithkline plc-spon adr (GSK) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company’s wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company’s nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

97,921 Employees
Last Reported Date: 02/26/15
Founded in 1935

glaxosmithkline plc-spon adr (GSK) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.0M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.2M GBP
Chairman of Global Vaccines, Executive Direct...
Total Annual Compensation: $2.3M
Compensation as of Fiscal Year 2014.

glaxosmithkline plc-spon adr (GSK) Key Developments

Padlock Therapeutics Accelerates Pipeline Development Through Agreement with GSK

Padlock Therapeutics announced that the company has entered into an agreement to license intellectual property and a collection of assets targeted at protein-arginine deiminases (PADs) from GSK Padlock plans to use these assets to expand the breadth and depth of its proprietary chemistry portfolio in an effort to create fundamentally new treatments for autoimmune disease by targeting the PAD enzymes. Clinical applications under evaluation at Padlock include rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. Under the terms of the agreement, Padlock will receive exclusive rights to a package of assets including intellectual property, selected compounds in several chemical series, assays, data and crystal structures developed by GSK scientists. In return, GSK will receive an undisclosed equity grant and board observer rights. Per the transaction, GSK receives no option to license or acquire Padlock assets nor does Padlock owe any future milestone or royalty payments.

University of North Carolina and GSK Announce Novel Partnership to Accelerate Search for HIV Cure

The University of North Carolina at Chapel Hill and GSK announced the creation of the dedicated HIV Cure center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS. This unique public-private partnership will redefine the traditional way of conducting research and create a new model to seek the breakthroughs needed to tackle an extraordinarily challenging global health issue. The HIV Cure center will be located on the UNC-Chapel Hill campus and will focus exclusively on finding a cure for HIV/AIDS. The new company, Qura Therapeutics, will handle the business side of the partnership, including intellectual property, commercialization, manufacturing and governance. Together, the HIV Cure center and Qura Therapeutics will serve as a catalyst for additional partners and public funding that will likely be needed to eradicate HIV worldwide. The collaboration is also expected to recruit and attract top talent from around the world.

Jing Ulrich Not Stand for Re-Election as Director of GlaxoSmithKline plc

GlaxoSmithKline plc announced that Jing Ulrich did not stand for re-election as directors, and stepped down from the board with effect from the conclusion of the AGM held on 7 May 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:US $44.11 USD -0.0399

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $158.86 USD -0.123
AbbVie Inc $66.85 USD -0.08
Bayer AG €128.75 EUR -2.36
Bristol-Myers Squibb Co $65.51 USD -0.97
Medtronic PLC $76.54 USD -0.16
View Industry Companies

Industry Analysis


Industry Average

Valuation GSK Industry Range
Price/Earnings 7.2x
Price/Sales 3.1x
Price/Book 9.7x
Price/Cash Flow 7.2x
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at